Drugs that contain Tadalafil
1. Adcirca patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5859006 | ELI LILLY CO | Tetracyclic derivatives; process of preparation and use |
Nov, 2017
(6 years ago) | |
| US6821975 | ELI LILLY CO | Beta-carboline drug products |
Nov, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5859006 (Pediatric) | ELI LILLY CO | Tetracyclic derivatives; process of preparation and use |
May, 2018
(5 years ago) | |
| US7182958 | ELI LILLY CO | β-carboline pharmaceutical compositions |
Apr, 2020
(3 years ago) | |
|
US7182958 (Pediatric) | ELI LILLY CO | β-carboline pharmaceutical compositions |
Oct, 2020
(3 years ago) | |
|
US6821975 (Pediatric) | ELI LILLY CO | Beta-carboline drug products |
May, 2021
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 22, 2012 |
| Orphan Drug Exclusivity(ODE) | May 22, 2016 |
Market Authorisation Date: 22 May, 2009
Treatment: Treatment of pulmonary hypertension
Dosage: TABLET;ORAL
ADCIRCA family patents
2. Cialis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5859006 | LILLY | Tetracyclic derivatives; process of preparation and use |
Nov, 2017
(6 years ago) | |
| US6821975 | LILLY | Beta-carboline drug products |
Nov, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6140329 | LILLY | Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence |
Jul, 2016
(7 years ago) | |
|
US5859006 (Pediatric) | LILLY | Tetracyclic derivatives; process of preparation and use |
May, 2018
(5 years ago) | |
| US7182958 | LILLY | β-carboline pharmaceutical compositions |
Apr, 2020
(3 years ago) | |
| US6943166 | LILLY | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Apr, 2020
(3 years ago) | |
|
US6943166 (Pediatric) | LILLY | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Oct, 2020
(3 years ago) | |
|
US7182958 (Pediatric) | LILLY | β-carboline pharmaceutical compositions |
Oct, 2020
(3 years ago) | |
|
US6821975 (Pediatric) | LILLY | Beta-carboline drug products |
May, 2021
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-219) | Feb 15, 2021 |
| Pediatric Exclusivity(PED) | Aug 15, 2021 |
| New Indication(I-642) | Oct 06, 2014 |
| New Indication(I-641) | Oct 06, 2014 |
Market Authorisation Date: 07 January, 2008
Treatment: Treatment of erectile dysfunction; Treatment of sexual dysfunction
Dosage: TABLET;ORAL
CIALIS family patents
3. Tadliq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11382917 | CMP DEV LLC | Liquid oral formulations for tadalafil |
Dec, 2038
(14 years from now) | |
| US11666576 | CMP DEV LLC | Liquid oral formulations for tadalafil |
Dec, 2038
(14 years from now) | |
Market Authorisation Date: 17 June, 2022
Treatment: Tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability
Dosage: SUSPENSION;ORAL
TADLIQ family patents